Cargando…
Residual Stroke Risk in Patients with Atrial Fibrillation Treated with Non-Vitamin K Oral Anticoagulants: An 8-Year Retrospective Cohort Study
BACKGROUND: Use of non-vitamin K antagonist oral anticoagulants (NOACs) for stroke prevention in non-valvular atrial fibrillation (NVAF) is common and significantly reduces stroke occurrence. Yet little is known about patients who have a stroke despite treatment. OBJECTIVE: The aim of this work was...
Autores principales: | Szeto, Cheuk Ling Charing, Hui, Kwok Fai |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7879322/ https://www.ncbi.nlm.nih.gov/pubmed/33461208 http://dx.doi.org/10.1159/000513105 |
Ejemplares similares
-
Non-Vitamin K Oral Anticoagulants for Stroke Prevention in Special Populations with Atrial Fibrillation
por: Bisson, Arnaud, et al.
Publicado: (2017) -
Non-vitamin K oral anticoagulants for secondary stroke prevention in patients with atrial fibrillation
por: Diener, Hans-Christoph, et al.
Publicado: (2020) -
Residual stroke risk despite oral anticoagulation in patients with atrial fibrillation
por: Carlisle, Matthew A., et al.
Publicado: (2022) -
Asian Patients with Stroke plus Atrial Fibrillation and the Dose of Non-Vitamin K Oral Anticoagulants
por: Bang, Oh Young, et al.
Publicado: (2016) -
Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants
por: Caturano, Alfredo, et al.
Publicado: (2019)